Tahseen Mozaffar
University of California, Irvine
H-index: 50
North America-United States
Top articles of Tahseen Mozaffar
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy | medRxiv | Nizar Chahin Gregory Sahagian Marc H Feinberg C Andrew Stewart Christopher M Jewell | 2024/1/4 |
Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes | Muscle & Nerve | Stacy R Lindborg Namita A Goyal Jonathan Katz Matthew Burford Jenny Li | 2024/4/9 |
P028: Switching treatment to cipaglucosidase alfa+ miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease | Genetics in Medicine Open | Priya Kishnani Barry Byrne Kristl Claeys Paula Clemens Jordi Díaz-Manera | 2024/1/1 |
A study to evaluate seroprevalence of antibodies to AAV8 and biomarkers in patients with late-onset Pompe disease: Rationale and study design | Molecular Genetics and Metabolism | Mark Walzer Ankita Shah Jill Malayang Miko Maruoka Chieri Hayashi | 2024/2/1 |
Treatment Fluctuations in Patients with Acetylcholine Receptor Antibody Positive Generalized Myasthenia Gravis on Maintenance Ravulizumab Treatment (P10-11.001) | Dave Ho Katherine Clifford Samantha Blum Miriam Freimer Neelam Goyal | 2024/4/14 | |
A Phase 1/2 first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of UX053 in patients with glycogen storage disease type III | Molecular Genetics and Metabolism | David F Rodriguez-Buritica Tahseen Mozaffar Giacomo P Comi Montserrat Morales-Conejo Han C Phan | 2024/4/1 |
Improvement in Myasthenia Gravis Activities of Daily Living Subdomain Scores in Patients Treated with Eculizumab: Results from a Generalized Myasthenia Gravis Registry Study … | Vern Juel Andrew Gordon Ericka Greene Tahseen Mozaffar James Winkley | 2024/4/14 | |
Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study | Research Square | Amy Doody Lindsay Alfano Jordi Diaz-Manera Linda Lowes Tahseen Mozaffar | 2023/10/6 |
Wrong Diagnoses Prior to the Ultimate Diagnosis of Late-onset Pompe Disease: A Multicenter Experience (P3-11.011) | Dennis Huang Marie Wencel Suur Biliciler Yessar Hussain Shafeeq Ladha | 2024/4/14 | |
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07) | Journal of Neurology | Benedikt Schoser Priya S Kishnani Drago Bratkovic Barry J Byrne Kristl G Claeys | 2024/2/28 |
Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease | Molecular Genetics and Metabolism | Antonio Toscano Barry J Byrne Kristl G Claeys Jordi Diaz-Manera Mazen M Dimachkie | 2024/2/1 |
Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21. 003) | Molecular Genetics and Metabolism | Tahseen Mozaffar Drago Bratkovic Barry J Byrne Kristl G Claeys Jordi Diaz-Manera | 2024/2/1 |
Recurring homozygous ACTN2 variant (p. Arg506Gly) causes a recessive myopathy | Annals of clinical and translational neurology | Sandra Donkervoort Payam Mohassel Melanie O'Leary Devon E Bonner Taila Hartley | 2024/2/4 |
Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practice | Muscle & Nerve | Nakul Katyal Karen Halldorsdottir Raghav Govindarajan Perry Shieh Suraj Muley | 2023/11 |
P021: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory and non-ambulatory patients with Pompe disease: An open-label phase I/II study (ATB200-02) | Genetics in Medicine Open | Priya Kishnani Benedikt Schoser Drago Bratkovic Paula Clemens Ozlem Goker-Alpan | 2023/1/1 |
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ARIMOCLOMOL IN PATIENTS WITH INCLUSION BODY MYOSITIS | BioPsychoSocial medicine | Pedro M Machado Richard J Barohn Michael McDermott Thomas Blaettler Thomas Lloyd | 2023/2/1 |
Muscle Pathology in a Case of Glycogen Storage Disease III (P6-8.014) | Khalid Alrasheed Tahseen Mozaffar Mari Perez-Rosendahl | 2023/4/25 | |
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 97 weeks: a phase 3 randomized clinical trial | JAMA neurology | Priya S Kishnani Jordi Diaz-Manera Antonio Toscano Paula R Clemens Shafeeq Ladha | 2023/6/1 |
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis | Annals of Neurology | Melanie Quintana Benjamin R Saville Matteo Vestrucci Michelle A Detry Lori Chibnik | 2023/9 |
P281 Quality of life in adults with dysferlinopathy: international clinical outcome study of dysferlinopathy | Neuromuscular Disorders | H Hilsden M James H Gordish Dressman J Day J Mendell | 2023/10/1 |
